This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is AngioDynamics (ANGO) Up 2.3% Since Last Earnings Report?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AngioDynamics (ANGO) Q4 Earnings Match Estimates, Revenues Top
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth across all its GBUs in fiscal 2021 Q4.
AngioDynamics (ANGO) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
AngioDynamics (ANGO) is optimistic about maintaining its robust product portfolio.
AngioDynamics (ANGO) Receives FDA Nod for AlphaVac System
by Zacks Equity Research
AngioDynamics (ANGO) gets 510(k) clearance from the FDA for the AlphaVac System for the non-surgical removal of thrombi or emboli from the vasculature.
AngioDynamics (ANGO) Up 4.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why You Should Hold AngioDynamics (ANGO) in Your Portfolio
by Zacks Equity Research
Investor optimism is high on AngioDynamics (ANGO) stock, courtesy of its solid prospects.
AngioDynamics (ANGO) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) witnesses revenue growth across two business segments in fiscal Q3.
AngioDynamics (ANGO) Soars 7.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
AngioDynamics (ANGO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
AngioDynamics (ANGO) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of 166.67% and 4.04%, respectively, for the quarter ended February 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: AngioDynamics (ANGO) Q3 Earnings Expected to Decline
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AngioDynamics (ANGO) at a 52-Week High: What's Driving It?
by Zacks Equity Research
AngioDynamics (ANGO) is optimistic about NanoKnife platform growth and the recent launch of Auryon Atherectomy.
Cooper Companies (COO) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Cooper Companies' (COO) fiscal first-quarter earnings reflect solid segmental performance.
Veeva Systems (VEEV) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Veeva Systems' (VEEV) core Subscription business and Professional Service segments perform impressively in fiscal Q4.
Patterson Companies (PDCO) Q3 Earnings Top Estimates, Up Y/Y
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal third-quarter 2021 results benefit from strong segmental performance.
Hologic (HOLX) Boosts Diagnostics Portfolio With New Buyout
by Zacks Equity Research
Hologic (HOLX) strengthens international capabilities and expands diagnostics arm across test menu, customer segments and geography with recent acquisition.
DENTSPLY SIRONA (XRAY) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) witnesses consumable revenue growth in the fourth quarter.
PRA Health (PRAH) Stock Down 2.8% Despite Q4 Earnings Beat
by Zacks Equity Research
PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the fourth quarter.
Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Glaukos' (GKOS) fourth-quarter results reflect rise in revenues and recovery in the U.S. Glaucoma franchise.
LHC Group (LHCG) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
LHC Group's (LHCG) fourth-quarter results benefit from organic growth in home health and hospice admissions.
Allscripts (MDRX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Allscripts (MRDX) witnessed expansion in gross margin, driven by better-than-expected software revenues and consistent decline in operating expenses.
Amedisys (AMED) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Amedisys (AMED) fourth-quarter 2020 revenues improve year over year, driven by strong growth across the Home Health and Hospice divisions.
Inogen (INGN) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Inogen's (INGN) fourth-quarter results benefit from higher rental revenues and strength in business-to-business revenues.
Nevro (NVRO) Q4 Loss Narrower Than Estimated, Revenues Miss
by Zacks Equity Research
Nevro's (NVRO) domestic and international revenues fell on a year-over-year basis in the fourth quarter.
Merit Medical (MMSI) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Merit Medical (MMSI) benefits from growth in revenues at the Cardiovascular segment in Q4.
Masimo (MASI) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Masimo (MASI) continues to gain from its key Product segment, which witnessed solid growth in Q4.